Skip to content

Evaluation of the RESTART Survival Programme

Evaluation of the RESTART Survival Programme

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06283511
Enrollment
200
Registered
2024-02-28
Start date
2025-03-01
Completion date
2026-12-31
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Breast Cancer

Brief summary

The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme.

Detailed description

Prospective longitudinal, single-centre, non-randomised study for patients who have completed acute treatment (surgery, radiotherapy, chemotherapy) for localised breast cancer within the last 3 months. In this project, investigtors are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme. The primary objective is to assess satisfaction with participation in the Restart programme and its various components. Evaluation criteria associated with the primary objective: Measurement of overall satisfaction and of the various components of the RESTART programme (Likert scale and open questions) \- Evaluation criteria associated with the secondary objective: To measure before starting the RESTART programme and 1 and 12 months after the end of the programme: * Patients' Quality of Life (QoL) (using the EORTC30 and BR23 questionnaires for breast cancer) * Health literacy (via the HLQ questionnaire) * Professional status * Patients' physical activity level via the Global Physical Activity Questionnaire (GPAQ) * Psychological distress, anxiety and depressive symptoms via the Generalized Anxiety Disorder - 7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) questionnaires * Fatigue (via the NRS) * Patient sleep quality using the Pittsburgh Sleep Quality Index (PSQI) To measure the rate of participation in the programme via the proportion of patients who participated in relation to the number of patients operated on for breast cancer located in Bordet during the same period.

Interventions

patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme

Sponsors

Jules Bordet Institute
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age \>= 18 at the time of signing the ICF 2. Minimum understanding of French 3. Signed study informed consent form obtained prior to any study-related procedure. 4. Participation in the RESTART programme 5. Patient with curative breast cancer (AJCC stage I-II-III)

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions.1 month after end of programme and 12 months after end of the programmeTo assess the global satisfaction with participation in the Restart programme and its various components via the Likert Scale.

Secondary

MeasureTime frameDescription
assessemnt of health literacy via HLQ questionnairebaseline - 1 month after end of programme - 12 months after end of programmeto mesure changes in health literacy via HLQ questionnaire
assessment of professional statusbaseline - 1 month after end of programme- 12 months after end of programmeto assess the number of patients who return to work via open question
assessment of level of physical activitybaseline - 1 month after end of programme- 12 months after end of programmeto measure the changes in level of physical activity via the Global Physical Activity Questionnaire (GPAQ)
assessment of quality of lifebaseline - 1 month after end of programme - 12 months after end of programmeTo measure changes in quality of life via EORTC30 questionnaire
assessment of the intensity of residual fatiguebaseline - 1 month after end of programme- 12 months after end of programmeto measure the intensity of residual fatigue via NRS (0= no fatigue and 10 = worst fatigue)
assessment of sleep qualitybaseline - 1 month after end of programme - 12 months after end of programmechanges in sleep quality via Pittsburgh sleep Quality index (PSQI) before and after participation in the RESTART programme.
Measuring the rate of participation in the programmebaseline - 1 month after end of programme - 12 months after end of programmeMeasure the participation rate in the program via the proportion of patients who participated compared to the number of patients operated on for breast cancer located in Bordet during the same period.
assessment of emotionnal distressbaseline - 1 month after end of programme- 12 months after end of programmeto measure the changes in emotional distress via questionnaire generalized Anxiety Disorder (GAD-7)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026